PrairieView Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

PrairieView Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$44K	Hold	100	–	–	﹤0.01%	200
2025 Q1	$48K	Hold	100	–	–	0.01%	193
2024 Q4	$40K	Sell	100 -45	-31%	-$20.9K	﹤0.01%	210
2024 Q3	$67K	Hold	145	–	–	0.01%	175
2024 Q2	$67K	Hold	145	–	–	0.01%	182
2024 Q1	$61K	Hold	145	–	–	0.01%	173
2023 Q4	$59K	Hold	145	–	–	0.01%	172
2023 Q3	$50K	Hold	145	–	–	0.01%	178
2023 Q2	$51K	Buy	+145	New	+$48.9K	0.01%	194

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PrairieView Partners's VRTX Position: Q2 2025 in Review

PrairieView Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2025 at 100 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #200.

PrairieView Partners first reported a position in VRTX in Q2 2023 and has held it in 9 quarters since. The position peaked at $67K in Q3 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

PrairieView Partners held 100 shares of Vertex Pharmaceuticals worth $44K as of Q2 2025.
PrairieView Partners left its Vertex Pharmaceuticals share count unchanged in Q2 2025.
Vertex Pharmaceuticals made up ﹤0.01% of PrairieView Partners's portfolio in Q2 2025, its #200 holding.
PrairieView Partners first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 9 quarters since.
PrairieView Partners's Vertex Pharmaceuticals position peaked at $67K in Q3 2024.
1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on PrairieView Partners's 13F filing for Q2 2025, filed 25 Jul 2025.